Exelixis Has Renewed Momentum Heading Into 2021

 
• By Jessica Merrill
Cancer cells on scientific background.3d illustration
Exelixis' Cabometyx won approval for first-line RCC combined with BMS' Opdivo last month, raising revenue expectations. • Source: Shutterstock

More from Business

More from Scrip